The State University of New York

Liposome Technology, Inc.

Cephalon, Inc.

Zeneus Pharma Limited

Eric Mayhew

Andrew S Janoff

Shaukat Ali

J Craig Franklin

Robert M Straubinger

Paul A Harmon

M Jane Ehrke

Francis C Szoka

Amarnath Sharma

Fred C Olson

Kenneth Mace

The present invention relates to a pharmaceutical composition for use in treatment of cancer patients. The composition includes at least one taxane present in a pharmaceutical effective amount and a mixture of one or more negatively charged phospholipids and one or more zwitterion (i.e. uncharged) phospholipids. This mixture entraps the at least one taxane in what is believed to be a liposome. The mixture contains a ratio of negatively charged phospholipids to zwitterion phospholipids of 1:9 to 7:3. The taxol is present in an amount of 1.5-8.0 mole percent taxane. The composition is in the form of particles having a size of 0.025 to 10 microns with substantially no taxane crystals.

Taxol formulation

A method for enhancing the therapeutic effectiveness of adriamycin, in the treatment of cancer, is disclosed. Liposomes containing coentrapped adriamycin and a secondary compound effective to reduce the toxicity of adriamycin or enhance the induction by adriamycin of the tumoricidal activity of host lymphoid cells, such as lipopolysaccharide, are administered parenterally in a therapeutically effective dose. In another aspect, macrophages stimulated in vivo with liposomes containing entrapped liposomes are exposed to an immunostimulator, for enhanced tumoricidal activity. Also disclosed are liposome compositions containing coentrapped adriamycin and an immunostimulator.

Liposome drug delivery method and composition

Growing community of inventors

South Wales, NY, United States of America

Eric Mayhew